Skip to main content
main-content

Connective tissue diseases

Systemic sclerosis

18-06-2019 | Systemic sclerosis | EULAR 2019 | News

Nintedanib reduces SSc-ILD progression across various subgroups

Nintedanib slows lung function decline in a variety of patients with systemic sclerosis-associated interstitial lung disease, suggests a subgroup analysis of data from the SENSCIS trial.

14-06-2019 | Systemic sclerosis | EULAR 2019 | News

Safety profile of nintedanib similar in SSc–ILD, IPF

Nintedanib’s safety and tolerability profile is similar in patients with systemic sclerosis-associated interstitial lung disease and those with idiopathic pulmonary fibrosis, according to a comparison of data from the SENSCIS and INPULSIS trials.

14-06-2019 | Systemic sclerosis | EULAR 2019 | News

Pirfenidone disappoints in SSc–ILD trial

Randomized trial findings presented at the EULAR 2019 congress in Madrid, Spain, suggest that pirfenidone does not stabilize or improve lung function in patients with systemic sclerosis-associated interstitial lung disease.

20-05-2019 | Systemic sclerosis | News

Nintedanib slows lung function decline in SSc-associated interstitial lung disease

Findings from the SENSCIS trial indicate that the tyrosine kinase inhibitor nintedanib reduces the annual rate of decline in forced vital capacity among patients with systemic sclerosis-associated interstitial lung disease.

28-03-2019 | Systemic sclerosis | News

Support for stroke prevention strategies in SSc patients

Individuals with systemic sclerosis have an elevated risk for ischemic stroke after adjustment for traditional cardiovascular risk factors, study findings suggest.

21-03-2019 | Systemic sclerosis | News

Progressive skin fibrosis should trigger enhanced monitoring in dcSSc

Progressive skin fibrosis is significantly associated with worsening lung function and an increased risk for death among patients with diffuse cutaneous systemic sclerosis, an analysis of EUSTAR data shows.

14-12-2018 | Pediatric | Article

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Jung JY et al. Pediatr Rheumatol 2018; 16: 79. doi: 10.1186/s12969-018-0296-z

A systemic sclerosis patient who has undergone autologous stem cell transplantation

Daniel Furst and Nihal Fathi present a case of a patient with diffuse systemic sclerosis who undergoes autologous hematopoietic stem cell transplantation after failing two other therapies.

14-12-2018 | Systemic sclerosis | Case study | Article

A systemic sclerosis patient who has undergone autologous stem cell transplantation

Daniel Furst and Nihal Fathi present a case of a patient with diffuse systemic sclerosis who undergoes autologous hematopoietic stem cell transplantation after failing two other therapies.

04-12-2018 | Comorbidities | Article

Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study

Panopoulos S et al. Arthritis Res Ther 2018. doi: 10.1186/s13075-018-1771-0

01-10-2018 | Systemic sclerosis | Article

Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis

Tennøe AH et al. J Am Coll Cardiol 2018; 72: 1804–1813. doi: 10.1016/j.jacc.2018.07.068

15-08-2018 | Systemic sclerosis | Review | Article

Major lung complications of systemic sclerosis

Denton CP, Wells AU, Coghlan JG. Nat Rev Rheumatol 2018; 14: 511–527. doi: 10.1038/s41584-018-0062-0

06-08-2018 | Systemic sclerosis | News

Rituximab may improve lung, skin manifestations of SSc

Results of an open-label randomized trial suggest that rituximab may be an appropriate alternative to cyclophosphamide for treating lung and skin disease associated with systemic sclerosis.

03-08-2018 | Pathophysiology | Review | Article

S100 proteins in rheumatic diseases

Austermann J, Spiekermann C, Roth J. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0058-9

26-07-2018 | Scleroderma | Article

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial

Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213

24-07-2018 | Systemic sclerosis | Article

Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: Results of a cross-sectional study

Lescoat A et al. Rheumatology(Oxford) 2018: key214. doi: 10.1093/rheumatology/key214

21-07-2018 | Systemic sclerosis | Review | Article

Pain and its management in systemic sclerosis

Merz EL, Assassi S, Malcarne VL. Curr Treat Options in Rheum 2018. doi: 10.1007/s40674-018-0104-4

15-07-2018 | Epidemiology | Article

Epidemiology and survival of systemic sclerosis-systemic lupus erythematosus overlap syndrome

Alharbi S et al. J Rheumatol 2018. doi: 10.3899/jrheum.170953

11-07-2018 | Systemic sclerosis | News

SSc more common in UK than previously thought

Results of a nationwide study suggest that the incidence and prevalence of systemic sclerosis in the UK may be higher than previous estimates suggest.

03-07-2018 | Vasculitis | Article

Oral cyclophosphamide in treatment of patients with refractory idiopathic inflammatory myopathies: A retrospective observational study

Bae S, Charles-Schoeman C. Clin Rheumatol 2018; 37: 2113–2123. doi: 10.1007/s10067-018-4174-3

Image Credits